Is Vertex Pharmaceuticals' Monopoly in Danger?
Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and marketed medicines -- the only ones in the world -- that target the underlying causes of a rare disease called cystic fibrosis (CF).
So far, Vertex's monopoly has remained intact despite many of its peers trying to break into this space. But could that change soon? Sionna Therapeutics, a privately held biotech, certainly hopes so.
Source Fool.com
Vertex Pharmaceuticals Inc. Stock
€456.30
1.110%
The stock is one of the favorites of our community with 54 Buy predictions and 2 Sell predictions.
On the other hand, the target price of 450 € is below the current price of 456.3 € for Vertex Pharmaceuticals Inc., so the potential is actually -1.38%.
